Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 5
2011 8
2012 7
2013 6
2014 1
2015 3
2016 4
2017 5
2018 5
2019 6
2020 19
2021 20
2022 22
2023 15
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Response.
Mauguen A. Mauguen A. Clin Trials. 2022 Dec;19(6):699. doi: 10.1177/17407745221125051. Epub 2022 Oct 5. Clin Trials. 2022. PMID: 36196870 Free PMC article. No abstract available.
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. Fabrizio VA, et al. Among authors: mauguen a. Blood Adv. 2022 Apr 12;6(7):1961-1968. doi: 10.1182/bloodadvances.2021006418. Blood Adv. 2022. PMID: 34788386 Free PMC article.
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Mundi PS, Dela Cruz FS, Grunn A, Diolaiti D, Mauguen A, Rainey AR, Guillan K, Siddiquee A, You D, Realubit R, Karan C, Ortiz MV, Douglass EF, Accordino M, Mistretta S, Brogan F, Bruce JN, Caescu CI, Carvajal RD, Crew KD, Decastro G, Heaney M, Henick BS, Hershman DL, Hou JY, Iwamoto FM, Jurcic JG, Kiran RP, Kluger MD, Kreisl T, Lamanna N, Lassman AB, Lim EA, Manji GA, McKhann GM, McKiernan JM, Neugut AI, Olive KP, Rosenblat T, Schwartz GK, Shu CA, Sisti MB, Tergas A, Vattakalam RM, Welch M, Wenske S, Wright JD, Canoll P, Hibshoosh H, Kalinsky K, Aburi M, Sims PA, Alvarez MJ, Kung AL, Califano A. Mundi PS, et al. Among authors: mauguen a. Cancer Discov. 2023 Jun 2;13(6):1386-1407. doi: 10.1158/2159-8290.CD-22-1020. Cancer Discov. 2023. PMID: 37061969 Free PMC article.
Translational Strategies for Repotrectinib in Neuroblastoma.
O'Donohue TJ, Ibáñez G, Coutinho DF, Mauguen A, Siddiquee A, Rosales N, Calder P, Ndengu A, You D, Long M, Roberts SS, Kung AL, Dela Cruz FS. O'Donohue TJ, et al. Among authors: mauguen a. Mol Cancer Ther. 2021 Nov;20(11):2189-2197. doi: 10.1158/1535-7163.MCT-21-0126. Epub 2021 Sep 4. Mol Cancer Ther. 2021. PMID: 34482287 Free PMC article.
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation.
Lakkaraja M, Scordo M, Mauguen A, Cho C, Devlin S, Ruiz JD, Klein E, Avecilla ST, Boulad F, Cancio MI, Curran KJ, Jakubowski AA, Kernan NA, Kung AL, O'Reilly RJ, Papadopoulos EB, Prockop S, van Roessel I, Scaradavou A, Shaffer BC, Shah G, Spitzer B, Tamari R, Giralt SA, Perales MA, Boelens JJ. Lakkaraja M, et al. Among authors: mauguen a. Blood Adv. 2022 Feb 8;6(3):1054-1063. doi: 10.1182/bloodadvances.2021005584. Blood Adv. 2022. PMID: 34788361 Free PMC article.
Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials.
Reed DR, Tulpule A, Metts J, Trucco M, Robertson-Tessi M, O'Donohue TJ, Iglesias-Cardenas F, Isakoff MS, Mauguen A, Shukla N, Dela Cruz FS, Tap W, Kentsis A, Morris CD, Hameed M, Honeyman JN, Behr GG, Sulis ML, Ortiz MV, Slotkin E. Reed DR, et al. Among authors: mauguen a. J Clin Oncol. 2024 Sep 1;42(25):2955-2960. doi: 10.1200/JCO.23.02717. Epub 2024 Jun 6. J Clin Oncol. 2024. PMID: 38843482
First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
Yeh R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park S, Brockway JP, Bromberg JF, Zhi WI, Robson ME, Sanford R, Modi S, Agnew BJ, Lyashchenko SK, Lewis JS, Ulaner GA, Zeglis BM. Yeh R, et al. Among authors: mauguen a. J Nucl Med. 2024 Mar 1;65(3):386-393. doi: 10.2967/jnumed.123.266392. J Nucl Med. 2024. PMID: 38272704 Free PMC article.
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents.
Moreno L, DuBois SG, Glade Bender J, Mauguen A, Bird N, Buenger V, Casanova M, Doz F, Fox E, Gore L, Hawkins DS, Izraeli S, Jones DTW, Kearns PR, Molenaar JJ, Nysom K, Pfister S, Reaman G, Smith M, Weigel B, Vassal G, Zwaan CM, Paoletti X, Iasonos A, Pearson ADJ. Moreno L, et al. Among authors: mauguen a. J Clin Oncol. 2023 Jun 20;41(18):3408-3422. doi: 10.1200/JCO.22.02430. Epub 2023 Apr 4. J Clin Oncol. 2023. PMID: 37015036 Free PMC article. Review.
120 results